Hintergrund
Regularien in Deutschland
Marker | Serologie | NAT |
---|---|---|
HBV | Anti-HBc a, HBsAg | – |
HCV | Anti-HCV | HCV |
HEV | – | HEV |
HIV-1/2 | Anti-HIV-1/2 | HIV-1/2 |
WNV b | – | WNV |
Syphilis | Anti-Treponema pallidum | – |
Marker | Testname | Hersteller | Testprinzip | Messprinzip |
---|---|---|---|---|
HBV DNA | cobas MPX (6800/8800 System) | Roche Diagnostics | Screening (multiplex) | PCR |
HBV DNA | cobas TaqScreen MPX Test, v2.0 | Roche Diagnostics | Screening (multiplex) | PCR |
HBV DNA | Procleix Ultrio Elite Assay | Grifols Diagnostic Solutions Inc | Screening (multiplex) | TMA |
HBV DNA | Procleix Ultrio Plus Assay | Grifols Diagnostic Solutions Inc | Screening (multiplex) | TMA |
HBV DNA | Procleix Ultrio Assay | Grifols Diagnostic Solutions Inc | Screening (multiplex) | TMA |
HBV DNA | Virus Screening PCR Kit, v1.3 | GFE Blut mbH | Screening (multiplex) | PCR |
HCV RNA | cobas MPX (6800/8800 System) | Roche Diagnostics | Screening (multiplex) | PCR |
HCV RNA | cobas TaqScreen MPX Test, v2.0 | Roche Diagnostics | Screening (multiplex) | PCR |
HCV RNA | Procleix Ultrio Elite Assay | Grifols Diagnostic Solutions Inc | Screening (multiplex) | TMA |
HCV RNA | Procleix Ultrio Plus Assay | Grifols Diagnostic Solutions Inc | Screening (multiplex) | TMA |
HCV RNA | Procleix Ultrio Assay | Grifols Diagnostic Solutions Inc | Screening (multiplex) | TMA |
HCV RNA | Virus Screening PCR Kit, v1.3 | GFE Blut mbH | Screening (multiplex) | PCR |
HEV RNA | cobas HEV (6800/8800 System) | Roche Diagnostics | Screening | PCR |
HEV RNA | Procleix HEV Assay | Grifols Diagnostic Solutions Inc | Screening | TMA |
Anti-HBc | Alinity i Anti-HBc II Reagenz | Abbott GmbH | Indirekt (Anti-Human-IgG, -IgM) | CMIA |
Anti-HBc | Alinity s Anti-HBc Reagenz | Abbott GmbH | Indirekt (Anti-Human-IgG, -IgM) | CMIA |
Anti-HBc | Architect Anti-HBc II Reagenz | Abbott GmbH | Indirekt (Anti-Human-IgG, -IgM) | CMIA |
Anti-HBc | Prism HBcore Reagenz | Abbott GmbH | Kompetitiv | CLIA |
Anti-HBc | Access HBc Ab | Beckman Coulter | Indirekt (Protein A) | CLIA |
Anti-HBc | Monolisa Anti-HBc Plus | Bio-Rad | Indirekt (Anti-Human-IgG, -IgM) | ELISA |
Anti-HBc | Liaison Anti-HBc | DiaSorin S.p.A. | Kompetitiv | CLIA |
Anti-HBc | Murex anti-HBc (total) | DiaSorin S.p.A. – UK Branch | Kompetitiv | ELISA |
Anti-HBc | Anti-HBc | Roche Diagnostics | Kompetitiv | ECLIA |
Anti-HBc | Elecsys Anti-HBc II | Roche Diagnostics | Kompetitiv | ECLIA |
Anti-HBc | Advia Centaur Anti-HBc Total (HBcT) | Siemens Healthcare Diagnostics | Sandwich | CLIA |
Anti-HBc | Advia Centaur HBc Total 2 (HBcT2) | Siemens Healthcare Diagnostics | Sandwich | CLIA |
Anti-HBc | Atellica IM Anti Hepatitis B core Total (HBcT) | Siemens Healthcare Diagnostics | Sandwich | CLIA |
Anti-HBc | Atellica IM HBc Total 2 (HBcT2) | Siemens Healthcare Diagnostics | Sandwich | CLIA |
HBsAg | Alinity i HBsAg Qualitative II Reagenz | Abbott GmbH | Sandwich | CMIA |
HBsAg | Alinity i HBsAg Reagenz | Abbott GmbH | Sandwich (quantitativ) | CMIA |
HBsAg | Alinity s HBsAg Reagenz | Abbott GmbH | Sandwich | CMIA |
HBsAg | Architect HBsAg Qualitative II Reagenz | Abbott GmbH | Sandwich | CMIA |
HBsAg | Prism HBsAg Reagenz | Abbott GmbH | Sandwich | CLIA |
HBsAg | Access HBsAg | Beckman Coulter | Sandwich | CLIA |
HBsAg | Liaison XL murex HBsAg Quant | DiaSorin S.p.A. | Sandwich (quantitativ) | CLIA |
HBsAg | Elecsys HBsAg II | Roche Diagnostics | Sandwich | ECLIA |
HBsAg | HBsAg II | Roche Diagnostics | Sandwich | ECLIA |
HBsAg | Advia Centaur HBsAg II (HBsII) | Siemens Healthcare Diagnostics | Sandwich | CLIA |
HBsAg | Atellica IM Hepatitis B surface Antigen II (HBsII) | Siemens Healthcare Diagnostics | Sandwich | CLIA |
Anti-HCV | Alinity i Anti-HCV Reagenz | Abbott GmbH | Indirekt (Anti-Human-IgG/IgM) | CMIA |
Anti-HCV | Alinity s Anti-HCV Reagenz | Abbott GmbH | Sandwich | CMIA |
Anti-HCV | Architect Anti-HCV Reagenz | Abbott GmbH | Indirekt (Anti-Human-IgG/IgM) | CMIA |
Anti-HCV | Prism HCV Reagenz | Abbott GmbH | Indirekt (Anti-Human-IgG) | CLIA |
Anti-HCV | Liaison XL murex HCV Ab | DiaSorin S.p.A. | Indirekt (Anti-Human-IgG) | CLIA |
Anti-HCV | HCV 3.0 ELISA Test System with Enhanced SAVe | Ortho – Clinical Diagnostics | Indirekt (Anti-Human-IgG) | ELISA |
Anti-HCV | Anti-HCV II | Roche Diagnostics | Sandwich | ECLIA |
Anti-HCV | Elecsys Anti-HCV II | Roche Diagnostics | Sandwich | ECLIA |
Anti-HCV | Advia Centaur Anti-HCV | Siemens Healthcare Diagnostics | Indirekt (Anti-Human-IgG) | CLIA |
Anti-HCV | Atellica IM Hepatitis C (aHCV) | Siemens Healthcare Diagnostics | Indirekt (Anti-Human-IgG) | CLIA |
HCV Ag/Ab | Murex HCV Ag/Ab Combination | DiaSorin S.p.A. – UK Branch | Sandwich | ELISA |
Prävalenz, Übertragung, Infektionsverläufe und Testung bei HBV, HCV und HEV
HBV
HCV
HEV
Nachweis erregerspezifischer Nukleinsäuren
Nachweis von Antikörpern gegen HCV
Nachweis des Hepatitis-B-Oberflächenantigens
Nachweis des Hepatitis-B-Core-Antigens
Anti-HBc-Reaktivität in 9 verschiedenen Anti-HBc-Tests | |||||
---|---|---|---|---|---|
Klasse | |||||
Gruppe | Reaktivität in zusätzlichen HBV-Markern | N Total (188) | A) 9 Tests | B) 5–8 Tests | C) < 5 Tests |
1) | Anti-HBc only | 13 (6,9 %) | 0 | 8 | 5 |
2) | Anti-HBc + Anti-HBs | 62 (33,5 %) | 50 | 11 | 2 |
Anti-HBc + Anti-HBe | 7 (3,7 %) | 7 | 0 | 0 | |
3) | Anti-HBc + Anti-HBs + Anti-HBe | 105 (55,9 %) | 105 | 0 | 0 |
Anti-HBc + Anti-HBs + HBV-DNA | 1 (0,53 %) | 1 | 0 | 0 | |
– | – | – | 162 (86,2 %) | 19 (10,1 %) | 7 (3,7 %) |
– | – | (168 (89,4 %) insgesamt Anti-HBs positiv) | |||
(112 (59,6 %) insgesamt Anti-HBe positiv) |